Indicators

Latest News about Eisai Co Ltd

Recent news which mentions Eisai Co Ltd

Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug

January 15, 2025

Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction

October 30, 2024

5 things to know before the stock market opens Monday

September 09, 2024

Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment

September 08, 2024

Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says

July 30, 2024

Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says

July 30, 2024

European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai

July 26, 2024

Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug

June 11, 2024

Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up

April 24, 2024

Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move

March 08, 2024

Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start

February 20, 2024

Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies

February 13, 2024

Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments

January 31, 2024

Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma

December 20, 2023

Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops

December 02, 2023

More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study

October 25, 2023

5 things to know before the stock market opens Tuesday

July 18, 2023

Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year

July 17, 2023

Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know

July 08, 2023

Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024

July 07, 2023

Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more

July 07, 2023

Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug

July 07, 2023

FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage

July 06, 2023

FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval

June 09, 2023

Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action

June 07, 2023

Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates

May 12, 2023

Bipartisan attorneys general call on Medicare to cover Alzheimer's treatments

May 01, 2023

Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe disease

April 30, 2023

Alzheimer's: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief says

April 26, 2023

Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says

April 25, 2023

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.